Deciphering leukemic B-cell chronic lymphoproliferative disorders

• Published in: Leukemia & lymphoma 2006-10, Vol.47 (10), p.2088-2095
• Main Authors: Ugo, Valérie, Leporrier, Nathalie, Salaun, Véronique, Letestu, Rémi, Radford-Weiss, Isabelle, Ramond, Sylvie, Nataf, Joelle, Guesnu, Martine, Picard, Françoise, Brouzes, Chantal, Perrot, Jean-Yves, Valensi, Françoise, Levy, Vincent, Ajchenbaum-Cymbalista, Florence, Troussard, Xavier
• Format: Article
• Language: English
• Subjects: Aged; Antigens, CD20 - biosynthesis; atypical chronic lymphocytic leukemia; B-cell chronic lymphoproliferative disorders; B-CLL; CD20; CD5 Antigens - biosynthesis; Cell Cycle; Cohort Studies; Cyclin D1 - biosynthesis; Cyclin-Dependent Kinase Inhibitor p27 - biosynthesis; Female; Humans; Immunophenotyping; Lymphoma, B-Cell - classification; Lymphoma, B-Cell - diagnosis; Lymphoma, B-Cell - genetics; Lymphoproliferative Disorders - classification; Lymphoproliferative Disorders - genetics; Lymphoproliferative Disorders - pathology; Male; Middle Aged; p27 kip1; Prognosis; Prospective Studies
• ISSN: 1042-8194; 1029-2403
• DOI: 10.1080/10428190600727939

Diagnosis of leukemic B-cell chronic lymphoproliferative disorders (B-CLPD) is a frequent challenge in hematology. In this multicentric study, we prospectively studied 165 new consecutive leukemic patients with B-CLPD selected on the basis of Royal Marsden Hospital scoring system ≤3. The primary aim of the study was to try to decipher the atypical cases and identify homogenous subgroups. Overall, morphological examination contributed to diagnosis in only 20% cases, all of them CD5 negative. Thirty additional cases were CD5 negative suggestive of leukemic marginal zone lymphoma in most cases. The significantly poorer survival of the 26 cyclin D1 positive cases justifies recommending its systematic determination among atypical B-CLPD. CD20 expression segregated clearly two subgroups among CD5 positive cyclin D1 negative B-CLPD. The 17 patients with the CD20 dim profile represent a homogeneous subgroup very close to typical B-cell chronic lymphocytic leukemia (B-CLL) on morphological, phenotypical and cytogenetical criteria. In contrast, the subgroup of 51 patients with a CD20 bright profile is heterogeneous. Their significantly lower p27 expression level suggest the presence of a proliferative component, underlying a more aggressive disease. Further genomic studies are warranted to establish their precise nature. These cases should not be included in the same therapeutic trials as B-CLL.